Webinar: How to Optimize Your T Cell Therapy Workflow—Without the Use of Serum or Feeder Cells by InsideScientific

How to Optimize Your T Cell Therapy Workflow—Without the Use of Serum or Feeder Cells

About

The development of safe and efficacious T cell therapies requires a wide range of reliable tools and technologies. To avoid costly delays and ensure a smoother transition from bench-to-bedside, scientists should use standardized reagents for their T cell cultures.

In this talk Dr. Dominika Nackiewicz will introduce how STEMCELL Technologies can help optimize your T cell cultures—with robust, high-performance products and expert support. You will learn how to generate high yields of functional T cells for cell therapy applications, without the use of serum or feeder cells. She will also discuss efficient gene editing strategies using the new CellPore™ Transfection System and solutions for T cell generation from pluripotent stem cells or hematopoietic progenitors.

Key learning objectives will include:

Generate high yields of functional T cells without the use of serum or feeder cells.

Achieve robust activation of T cells in a bead-free, soluble, robust T cell activator.

Learn how to effectively generate T cells from pluripotent stem cells or hematopoietic progenitors.

Optimize your T cell therapy development and manufacturing workflow with the right tools and reagents.

Presenters

Dominika Nackiewicz, PhD

Product Manager, Immunology, STEMCELL Technologies

Dr. Nackiewicz received her PhD in Experimental Medicine from The University of British Columbia and received additional immunology training at University of Virginia and Yale University. She is currently a Product Manager for immunology and immune cell culture applications at STEMCELL Technologies, where she helps to convert new ideas into innovative, reliable products.

Tim Le Fevre

Senior Scientist, STEMCELL Technologies

Tim Le Fevre is a Senior Scientist working as part of the Immunology – Culture & Applications team within the Research & Development department at STEMCELL Technologies. He has worked at STEMCELL for more than 10 years developing cell culture products to support the growth and differentiation of various immune cells. Recently, Tim worked on developing STEMdiff™ and StemSpan™ immune cell kits that enable researchers to differentiate human pluripotent stem cells or cord blood-isolated hematopoietic stem and progenitor cells into monocytes, T cells, or NK cells.

Jessie Yu, MD

Dr. Jessie Yu is a Senior Scientist at STEMCELL Technologies, where she has spent 14+ years developing new products in immune cell research. Her expertise ranges from immune cell isolation to human T cell activation and expansion. She received her MD in 2001 from Shandong University and MSc in Immunology in 2006 from the Univeristy of British Columbia. With a background in medicine and immunology research, Dr. Yu firmly believes in adoptive cell therapy as a breakthrough tool to treat many diseases. She is committed to introducing innovative products and applications to the field.

Reserve Your Spot

First Name*

Last Name*

Email Address*

Organization / Company*

Job Title*

Country / Region*

At which stage of research are you currently?*

Fundamental research

Early preclinical

Late preclinical/process development

Clinical (Phase I–III)

Commercialization

I don't know

Not applicable

What part of your T cell workflow do you find the most challenging? *

Cell sourcing

Cell isolation

Cell expansion

Cell activation

Cell engineering

Other

I do not work with T cells

Please post any questions you might have for the speakers in the field below:

utm_bmcr_source